Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Polepally AR, et al. Among authors: dumas eo. Clin Pharmacokinet. 2016 Aug;55(8):1003-14. doi: 10.1007/s40262-016-0373-8. Clin Pharmacokinet. 2016. PMID: 26895022 Free PMC article. Clinical Trial.
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-Matias T, Lu W, Cohen DE, Feld JJ. Welzel TM, et al. Among authors: dumas eo. Lancet Gastroenterol Hepatol. 2017 Jul;2(7):494-500. doi: 10.1016/S2468-1253(17)30071-7. Epub 2017 Apr 14. Lancet Gastroenterol Hepatol. 2017. PMID: 28416221 Clinical Trial.
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C. Talal AH, et al. Among authors: dumas eo. J Infect Dis. 2018 Jan 17;217(3):474-482. doi: 10.1093/infdis/jix495. J Infect Dis. 2018. PMID: 29228392 Free PMC article. Clinical Trial.
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Alqahtani S, et al. Among authors: dumas eo. J Viral Hepat. 2017 Apr;24(4):280-286. doi: 10.1111/jvh.12641. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935166
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM. DeGoey DA, et al. J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15. J Med Chem. 2014. PMID: 24400777
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
Grebely J, Dore GJ, Alami NN, Conway B, Dillon JF, Gschwantler M, Felizarta F, Hézode C, Tomasiewicz K, Fredrick LM, Dumas EO, Mensa FJ. Grebely J, et al. Among authors: dumas eo. Int J Drug Policy. 2019 Apr;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. Epub 2019 Feb 6. Int J Drug Policy. 2019. PMID: 30735896 Free article.
17 results